Dr Reddy’s Laboratories aims to earn $1 billion revenue a year from branded generics for the next three years. One of the leading Indian drug makers, Dr Reddy’s sold generic drugs worth $600 million globally in the nine months of this fiscal ended December 31. The company’s flagship brand, Omez, alone brings in Rs 700 crore revenues to the company.
The company had filed 141 ANDAs to the US FDA till December 2010. The company is awaiting approval for 62 ANDAs. Of these, 35 ANDAs were filed with Para IV; and 13 are first-to-file products. he key future growth trigger for the company will be the opportunity arising due to off-patenting of some of the blockbuster drugs worth $80-100 billion in the next five years.
Some of the drugs like Pfizer’s Lipitor will be off- patent in the next three to four years. Dr Reddy’s as a generic drug maker is well positioned to take the opportunities. Though the market size in terms of value comes down after the patent expiry, generic players will have sizable opportunity.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: